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ABSTRACT 
Alcoholic liver disease (ALD) is a leading cause of morbidity and mortality in India. Chronic 
consumption of alcohol results in variations in alcohol metabolism, oxidative stress, antigenic 
adducts formation and acetaldehyde toxicity. These factors cause inflammation, fatty changes, 
fibrosis of liver cells and raising the transaminases in the blood. There is no specific treatment for 
ALD.  
Patola Katurohinyadi Kashayam, a classical Ayurvedic formulation has been reported by many 
practitioners to be effective in treatment of liver disorders. This study focuses on the effect of the 
Patola Katurohinyadi Kashayam in ALD for restoration of normal liver function by investigating 10 
subjective and 5 objective parameters. As Patola Katurohinyadi Kashayam is Raktaprasadak, 
Yakritgami, Deepan, Jwaraghna, Kamalanashak and Pandunashak it was used as Trial Drug.  
Clinical Trials were conducted at Anandvan De-Addiction Centre, Pune. By random allotment method 
20 well-diagnosed patients of ALD were included in both Control and Trial group each. The diagnosis 
of ALD was made by documentation of alcohol excess and evidence of liver disease. Trial group was 
administered the Trial drug in a dose of 15ml with luke warm water after meal for the duration of 28 
days. Control group was not given any drugs but observed for 28 days for all parameters.  
The statistical analysis revealed that Trial drug is effective in ALD and significantly reduces Panduta, 
Agnimandya, Hrullas, Daha and Daurbalya. Besides it significantly lowers the SGOT and SGPT levels 
too. 
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INTRODUCTION
Alcoholic liver disease (ALD), a toxic liver 
injury is a leading cause of morbidity and mortality in 
India. In 2012, about 3.3 million deaths, or 5.9% of all 
global deaths were attributable to alcohol consumption 
[1]. The spectrum of ALD varies from simple steatosis to 
cirrhosis. These are not necessarily distinct stages of 
evolution of the disease, but rather, multiple stages that 
may be present simultaneously in a given individual[2,3]. 
These are often grouped into three histological stages 
of ALD, including fatty liver or simple steatosis, 
alcoholic hepatitis (AH), and chronic hepatitis with 
hepatic fibrosis or cirrhosis[4].  
The primary metabolite of alcohol i.e. 
Acetaldehyde is thought to be a major cause of 
alcoholic liver disease. Acetaldehyde impairs 
mitochondrial oxidative system resulting in variations 
in alcohol metabolism, centrilobular hypoxia; 
inflammatory cell infiltration and activation, antigenic 
adducts formation, reactive oxygen species formation 
and lipid peroxidation[5-8]. These factors cause 
inflammation, fatty changes, fibrosis of liver cells. The 
range of clinical features of alcoholic liver disease 
varies, from asymptomatic to end-stage liver disease 
with portal hypertension, jaundice and encephalopathy 
Patients may present symptoms such as nausea, 
anorexia, fever, ascites and jaundice[8]. A number of 
laboratory abnormalities, including elevated AST and 
ALT have been reported in patients with ALD, and used 
to diagnose ALD[9]. 
The symptoms of ALD often improve with the 
cessation of drinking. Immediate and total abstinence 
from alcohol is critical for patients with alcoholic liver 
disease. Continued drinking is associated with disease 
progression, while abstinence benefits patients at any 
stage of disease. There is no specific treatment for ALD.  
According to Charak, Madya (Alcohol) is 
etiological factor responsible for vitiation of 
Raktadhatu[10]. Excessive alcohol consumption 
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ultimately causes vitiation of Yakrit (Liver) as Yakrit is 
Mulasthana of Raktavaha Srotas[11]. This can be 
correlated as Alcoholic Liver Disease. The signs and 
symptoms of ALD are similar to that of Kamala Vyadhi. 
Patola Katurohinyadi Kashayam[12] is a classical 
Ayurvedic formulation from Ashtanga Hridayam, has 
been reported to many health practitioners to be 
effective in treatment of Liver disorders. It is indicated 
in Kamala, Kushtha, Vaman, Aruchi, Jwara and 
Vishajanya Vyadhi [12]. Almost all the ingredients of this 
Kashaya like Patola, Kutki, Raktachandan, Murva, 
Guduchi and Patha are Raktaprasadak, Pittaghna, 
Kamalanashak, Pandunashak and Vishaghna. This 
Kashaya is easy to administer and cost effective. Thus 
to counteract ALD Patola Katurohinyadi Kashayam was 
selected as it has an affinity for Yakrit and Rakta Dhatu. 
AIMS AND OBJECTIVES 
The study was conducted with the aim to 
assess the effect of Patola Katurohinyadi Kashayam in 
ALD. The objective was to ascertain the restoration of 
normal liver functions. 
MATERIALS AND METHOD 
Patola Katurohinyadi Kashayam was 
purchased from Arya Vaidya Sala Kottakkal, Kerala. 
Standardization certificate of the same was obtained 
prior to commencement of the clinical study. The 
Patola Katurohinyadi Kashayam used was as per the 
reference of Ashtanga Hridayam [12].  
This Open Randomized Clinical Trial was 
conducted at Anandvan De-addiction and 
Rehabilitation Centre, Chandan Nagar, Pune, India after 
the permission of the Institutional Ethics Committee 
(vide letter no: BVDU/Exam/2185/2011-12).  
Patients diagnosed with ALD were randomly 
selected from the in-patient departments of Anandvan 
De-addiction and Rehabilitation Centre, Chandan 
Nagar, Pune, India. 
Method of collection of data 
Detailed clinical history and clinical 
examination was carried out before assessing the case 
and starting the proper trial. The diagnosis of ALD was 
made by documentation of alcohol excess and evidence 
of liver disease using the special Proforma. The patients 
were divided into two groups - Control group and Trial 
group. The both groups consisted of 20 patients each. 
Thus, the total sample size of the study was 40, 
calculated on the basis of rate of incidence of the 
condition. A total 112 patients were screened and 62 of 
them were enrolled in the study, but a dropout of 22 
was registered. Informed Consent of each patient was 
taken prior to their enrolment in the clinical trials. 
The Trial Group patients were administered 15 
ml of Patola Katurohinyadi Kashayam two times a day 
after meals with luke warm water. Patients of the 
Control Group did not receive any trial drug. All 
patients, who were included in study, were studied 
daily for 28 days. All patients were subjected to pre and 
post laboratory investigations of Haemogram and Liver 
Function Test (LFT). 
Inclusion Criteria 
a) Clinically diagnosed patients of Alcoholic Liver 
Disease were selected 
b) Age group - above 18 years (as patients below this 
category were negligible in the centre)  
c) Sex - Male (as female were not admitted in this 
particular centre)  
Exclusion Criteria 
a. Age below 18 years  
b. Sex - Female  
c. Patients suffering from non alcoholic hepatitis 
d. Patients with high risk diseases and severe illness  
e. Patients who are diagnosed as Liver cirrhosis, 
Hepatic coma, Ascites, Portal hypertension, 
Splenomegaly, Hepatocellular carcinoma etc.  
Assessment Criteria: The patients were assessed 
using the following parameters. 
Subjective Parameters 
1. Assessment of Agnimandya (Loss of Appetite) 
0 : Absent 
1 : Present 
2. Assessment of Aruchi (Tastelessness) 
0 : Absent 
1 : Present 
3. Assessment of Hrillas (Nausea) 
0 : Absent 
1 : Nausea 
2 : Nausea with excess salivation 
3 : Nausea with regurgitation 
4 : Nausea with vomiting 
4. Assessment of Trishna (Thirst) 
0 : Absent 
1 : Mild 
2 : Moderate 
3 : Sever but reduces after water intake 
4 : Sever but don’t reduces after water intake 
5. Assessment of Manda Jwara (Mild Fever) 
0 : Absent 
1 : Present 
6. Assessment of Daha (Burning sensation) 
0 : Absent 
1 : Present 
7. Assessment of Panduta (Pallor) 
0 : Absent 
1 : Present 
8. Assessment of Pitatva (Icterus) 
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0 : Absent 
1 : Present 
9. Assessment of Daurbalya (Weakness) 
0 : Absent  
1 : Dyspnoea after moderate to severe work  
2 : Dyspnoea after mild to moderate work 
3 : Dyspnoea after mild work  
4 : Dyspnoea at rest 
10. Assessment of Bhrama (Vertigo) 
0 : Absent  
1 : Occasionally  
2 : Frequently 
3 : Often and with short disorientation  
4 : More often and with prolonged disorientation 
Objective Parameters 
1. Haemogram 
2. Liver Function Test 
STATISTICAL ANALYSIS 
Statistical analysis was carried out in terms of 
Mann‐Whitney U test, paired t-test and finally results 
were incorporated in term of probability (p). 
Table 1: Showing effect on subjective parameters between Trial and Control group 
Symptoms Group Median grade at 
Day 0 Day 7 Day 14 Day 21 Day 28 
Agnimandya Trial 1 1 1 0 0 
Control 1 1 1 1 1 
p-value 0.999 0.999 0.289 0.06 0.006 
Aruchi Trial 1 1 0 0 0 
Control 1 1 1 0 0 
p-value 0.602 0.602 0.108 0.999 0.289 
Hrillas Trial 3 2.5 2 0.5 0 
Control 3 2 1.5 1 1 
p-value 0.62 0.01 0.999 0.03 0.006 
Trishna Trial 2 2 1 0 0 
Control 2 1 0 0 0 
p-value 0.841 0.052 0.253 0.289 0.602 
Manda Jwara Trial 1 1 1 0 0 
Control 1 1 0 0 0 
p-value 0.602 0.799 0.602 0.999 0.799 
Daha Trial 1 1 0 0 0 
Control 1 1 1 0 0 
p-value 0.799 0.799 0.602 0.183 0.03  
Panduta Trial 1 1 1 0 0 
Control 1 1 1 1 1 
p-value 0.999 0.999 0.152 0.003 <0.001  
Pitatva Trial 1 1 1 0 0 
Control 1 1 1 1 0 
p-value 0.999 0.999 0.602 0.183 0.108 
Dourbalya Trial 2 2 1 1 1 
Control 3 2 2 1 1 
p-value 0.231 0.341 0.091 0.341 0.049 
Bhrama Trial 0 0 0 0 0 
Control 1 0 0 0 0 
p-value 0.102 0.678 0.429 0.799 0.799 
Out of total 10 subjective parameters highly significant result was observed in the symptom Panduta (p-
value < 0.001) Significant results were observed in 4 symptoms Agnimandya, Hrillas, Daha and Daurbalya 
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Table 2: Showing effect on objective parameters between Trial and Control group 
Biomarkers  Group N Mean SD p-value 
HB_BT Trial 20 12.67 2.60  
Control 20 13.45 1.67 0.267 
HB_AT Trial 20 13.60 1.94  
Control 20 13.81 1.51 0.698 
Bil_Total_BT Trial 20 1.79 1.13  
Control 20 1.49 0.66 0.310 
Bil_Total_AT Trial 20 0.79 0.22  
Control 20 0.82 0.16 0.637 
Bil_Direct_BT Trial 20 0.86 0.84  
Control 20 0.85 0.54 0.952 
Bil_ Direct _AT Trial 20 0.46 0.67  
Control 20 0.42 0.15 0.795 
Bil_Indirect _BT Trial 20 0.93 0.40  
Control 20 0.64 0.22 0.009 
Bil_Indirect _AT Trial 20 0.49 0.19  
Control 20 0.41 0.11 0.117 
SGPT_BT Trial 20 89.70 50.82  
Control 20 92.70 29.86 0.821 
SGPT_AT Trial 20 31.24 6.46  
Control 20 47.28 9.80 < 0.001  
SGOT_BT Trial 20 108.10 57.58  
Control 20 79.73 27.37 0.057 
SGOT_AT Trial 20 24.44 9.03  
Control 20 36.94 7.35 < 0.001  
ALP _BT Trial 20 288.70 68.78  
Control 20 202.87 52.71 < 0.001 
ALP _AT Trial 20 151.54 40.98  
Control 20 136.83 37.65 0.244 
HB = Haemoglobin, Bil = Bilirubin, SGOT = Serum glutamic oxaloacetic transaminase, SGPT = Serum 
glutamic pyruvic transaminase, ALP = Alkaline phosphatase, BT = before treatment, AT = after treatment, 
N= number of patients, SD =Standard Deviation, p = Probability Value 
In objective parameters, highly significant 
results were observed in the SGOT and SGPT (as p-
value < 0.001) 
OBSERVATIONS & RESULTS  
Based on the statistical analysis, the effects of 
the drug on various parameters were studied and 
following results were obtained. The symptom Panduta 
showed complete i.e. 100% reduction in Trial group 
while 25% reduction in Control group [Fig.1]. 
Agnimandya showed 90% relief in Trial group and 40% 
in Control group [Fig.2]. Hrillas was reduced by 85% in 
Trial group as compared to 35% in Control group 
[Fig.3] while Daha showed 100% reduction in the Trial 
group and 60% reduction in Control group [Fig.4]. 
Daurbalya was reduced by 35% in Trial group and 20% 
in Control group. Bhrama recorded an alleviation of 
100% in Trial group whereas the Control group 
showed only 80% alleviation. Similarly Aruchi showed 
90% reduction in Trial group while 80% reduction in 
Control group [Fig.5] whereas Pitatva was reduced by 
100% in Trial group as compared to 70% in Control 
group [Fig.6]. 
The Liver Function Test viz., Total Bilirubin, 
Indirect Bilirubin, SGPT [Fig.7], SGOT [Fig.8] and 
Alkaline Phosphatase showed a greater decrease in the 
mean difference in Trial group indicating the efficacy of 
Trial drug. 
DISCUSSION 
Patola Katurohinyadi Kashayam is a 
combination of 6 herbal ingredients [12] viz. Patola 
(Trichosanthes dioica), Katurohini (Picrorhiza kurroa), 
Raktachandan (Pterocarpus santalinus), Murva 
(Marsdenia tenacissima), Guduchi (Tinospora 
cordifolia), Patha (Cissampelos pareira). 
Patola root decoction is having hepatocurative 
and mild hepatoprotective activity due to its Rechaka 
property. It’s Pittasaraka (cholagogue), Deepan, 
Pachan, Anuloman and Bhedan properties help to 
alleviate ALD [13].  
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Katurohini is useful in jaundice, nausea 
anorexia, dyspepsia and periodic fevers and proven as 
a hepatoprotective agent in experimental & clinical 
studies. It has shown hydrocholeretic effect in rats and 
dogs [14]. Its extract revealed strong antioxidant activity 
and also significantly inhibited lipid peroxidation [15]. 
Picroliv, its active constituent has been evaluated as a 
hepatoprotective agent against ethanol-induced 
hepatic injury in rats [16-17].  
 The ethanol and aqueous stem bark extract of 
Raktachandan afforded significant protection against 
CCl4 induced hepatocellular injury[18].  
 Murva has Deepan, Vishaghna, Anuloman, 
Amapachan, Shulaprashaman and Pittasaraka property. 
It also has anti-inflammatory, antibacterial, 
antimutagenic, anticancer and anti-pyretic action. 
 Various Ayurvedic preparations of Guduchi are 
indicated in Pandu (anaemia) and Kamala (jaundice). A 
clinical study has shown that Guduchi plays an 
important role in normalization of altered liver 
functions (ALT, AST).The anti hepatotoxic activity of 
Tinospora cordifolia has been demonstrated in CCl4 
induced liver damage, normalising liver function as 
assessed by morphological, biochemical (SGPT, SGOT, 
serum alkaline phosphatase, serum Bilirubin) 
parameters[19-20]. 
 Hepato protective activity of Patha 
(Cissampelos pareira) against carbon tetra chloride 
induced hepatic damage was found in vitro and in vivo 
study [21]. 
All liver disorders are due to the vitiation of 
Pitta and Virechana is the choice of treatment for all the 
Pittaja rogas. Patola Katurohinyadi Kashayam is a 
madhyam shodhan formulation stated in Ashtanga 
Hridayam Shodhanadi ganasangrah adhyaya. It is Tikta 
(bitter) rasa predominant which is Pittashamaka in 
nature. This predominance also attributes to the 
Vishanasaka (Anti-toxic) property as stated by classics. 
Similarly Laghu guna (light) allows easy absorption 
and assimilation. The Bhedana property of Trial drug is 
especially correlated with choleretics. The drug which 
has choleterics property will stimulate the secretion of 
bile and the excessive bile cause Virechana. In short 
trial drug has choleretic, hepatoprotective, 
hepatocurative and antioxidant property. 
CONCLUSION 
From the above study, an inference can thus be 
drawn that Patola Katurohinyadi Kashayam is a very 
potent polyherbal formulation that effectively reduces 
the symptoms of Panduta, Agnimandya, Aruchi, Hrillas, 
Trishna, Daha and Bhrama observed in patients 
suffering from ALD. It is also effective in restoration of 
normal liver functions as it reduces elevated SGPT and 
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Graph 1: Showing effect on subjective parameters between Trial and Control group 
  
